Peptide Study Protocols: How Trials Structure Duration and Breaks

Discussion of peptides outside the literature often borrows language from other fields: a "cycle" of a set number of weeks, followed by a "break" of equal length. The published clinical literature is structured differently. Trials define a treatment period of fixed length, often preceded by a dose-escalation run-in, measured at pre-specified checkpoints, and in some cases followed by an off-treatment observation phase. This page summarises what those published protocols looked like, how frequently administration occurred in them, and what researchers reported when treatment was continued or withdrawn. It describes studies; it does not describe what any individual should do.

This page is for educational purposes only and is not medical advice; consult a licensed physician for any question about a specific compound, schedule, or health condition.

What "Cycle Length" Corresponds To in Trial Design

In the peptide literature most closely tied to metabolic research — the glucagon-like peptide-1 (GLP-1) receptor agonists and related polyagonists — protocols were built from four components rather than a single "cycle":

• A titration or run-in phase, in which the dose was escalated stepwise over several weeks before the target dose was reached.
• A maintenance treatment period at the target dose, lasting a fixed number of weeks or months.
• Scheduled assessment points, typically at intervals such as 3, 6, 12 months or at a single primary endpoint week.
• An off-treatment phase in a subset of studies, used to observe what happened after administration ended.

None of the trials summarised here randomised participants to alternating on-and-off blocks. Where treatment stopped, that stop was either the end of the trial or a deliberate withdrawal comparison — not a scheduled "break" intended to be resumed.

How Long Treatment Periods Ran

The 68-week design

A recurring duration in obesity-focused peptide research is 68 weeks. In the STEP 1 trial, researchers administered once-weekly subcutaneous semaglutide 2.4 mg or placebo for 68 weeks alongside lifestyle intervention and reported a mean change in body weight of −14.9% with semaglutide versus −2.4% with placebo (PMID 33567185). The same 68-week framework was used in a trial of adults with obesity and knee osteoarthritis, where once-weekly semaglutide 2.4 mg was reported to produce a mean body-weight change of −13.7% versus −3.2% with placebo, along with a greater reduction in WOMAC pain score (PMID 39476339).

Run-in plus randomised continuation

STEP 4 illustrates how a protocol can separate escalation from maintenance. In that study, all participants received a 20-week run-in with dose escalation to once-weekly semaglutide 2.4 mg, after which they were randomised to continue the same dose or switch to placebo for a further 48 weeks; the continued-treatment group was reported to lose a further 7.9% of body weight while the placebo-switch group regained 6.9% (PMID 33755728). The 20-week figure is informative because it shows how much of a published schedule can be occupied by escalation rather than target-dose exposure.

Multi-year designs

Cardiovascular outcome trials ran far longer than weight-loss trials. In a trial of 17,604 adults with overweight or obesity and established cardiovascular disease but without diabetes, once-weekly semaglutide 2.4 mg was compared with placebo over a mean follow-up of 39.8 months, and researchers reported a primary cardiovascular composite event rate of 6.5% versus 8.0% (PMID 37952131). For the once-daily peptide liraglutide, the LEADER trial followed participants with type 2 diabetes for a median of 3.8 years and reported lower rates of cardiovascular death and death from any cause compared with placebo (PMID 27295427). These are the longest continuous administration periods in the verified literature discussed here, and in both the compound was given without scheduled interruption.

Shorter measurement checkpoints

Some analyses reported outcomes at earlier intervals rather than at a single long endpoint. A comparative study of semaglutide and tirzepatide in adults with overweight or obesity reported weight change at 3, 6 and 12 months of treatment, with greater weight reduction observed in the tirzepatide group at each checkpoint (PMID 38976257). That design shows change accumulating progressively across months rather than plateauing at a short fixed "cycle" boundary.

How Often Administration Occurred in Published Protocols

Administration frequency in these trials was a property of the compound's pharmacology, not a variable participants adjusted. Semaglutide protocols in the obesity literature used once-weekly subcutaneous injection at a 2.4 mg target dose across 68-week and multi-year designs (PMID 33567185, PMID 37952131). Liraglutide, by contrast, was given as a once-daily subcutaneous injection in the LEADER cardiovascular outcome trial (PMID 27295427). A network meta-analysis covering seven GLP-1 receptor agonists and polyagonists for weight loss compared agents that differed in both dosing interval and molecular target, and reported differences between them in weight-loss magnitude (PMID 39305981). Frequency, in other words, varied across compounds within the same therapeutic class, which is one reason a single "how often" answer does not transfer across peptides.

A Summary Chart of Published Trial Schedules

The table below condenses the schedule structure reported in each cited study. Every figure is traceable to the linked record.

What Happened When Trials Stopped Treatment

The closest the literature comes to studying a "break" is deliberate withdrawal. In the STEP 1 trial extension, researchers followed participants for one year after both semaglutide and lifestyle intervention were withdrawn and reported that participants regained about two-thirds of their prior weight loss, with improvements in cardiometabolic variables reverting toward baseline (PMID 35441470). The STEP 4 randomised comparison pointed the same direction within an ongoing trial: switching to placebo after the run-in was followed by a reported 6.9% weight regain over 48 weeks, while continued treatment was followed by further loss (PMID 33755728).

These single-trial findings were examined collectively in a 2025 systematic review and meta-analysis of discontinuing GLP-1 receptor agonists, which pooled studies of body habitus after stopping and reported regain of body weight following discontinuation across the included populations (PMID 40186344). Taken together, the withdrawal literature frames duration as a determinant of the observed effect rather than as an arbitrary boundary: in these studies the reported changes tracked ongoing administration.

Were Planned Breaks Ever Tested?

Informal community discussion frequently describes peptide use as alternating blocks of weeks on and weeks off. That structure does not appear as a randomised comparison in the verified literature summarised here. Systematic reviews of GLP-1 receptor agonists for weight loss in adults without diabetes described trials of continuous weekly or daily administration and reported efficacy and safety across those continuous designs (PMID 39761578). A separate meta-analysis of once-weekly subcutaneous semaglutide in overweight or obesity without diabetes likewise pooled continuous-dosing randomised trials when reporting weight-loss effects (PMID 38923272). Because no cited trial randomised participants to intermittent scheduling, the literature provides no comparative data on whether inserting breaks changes outcomes — an absence of evidence rather than evidence of equivalence.

Tolerability Across Trial Durations: What Studies Report

Adverse-event reporting in these protocols was tied to the same fixed periods. A systematic review and meta-analysis of semaglutide for weight loss in obesity without diabetes reported that gastrointestinal events such as nausea, vomiting, diarrhoea and constipation were the most common adverse events observed with semaglutide compared with placebo (PMID 36578889). In STEP 1, researchers reported nausea and diarrhoea as the most frequent adverse events, typically transient and mild-to-moderate, with a proportion of participants discontinuing because of gastrointestinal events over the 68-week period (PMID 33567185). The 2025 Annals systematic review of GLP-1 receptor agonists in adults without diabetes similarly reported gastrointestinal adverse events and treatment discontinuation as the principal safety findings across included randomised trials (PMID 39761578). The stepwise escalation run-ins used in these protocols were a structural feature of the designs in which those tolerability patterns were observed (PMID 33755728).

How the Reviews Frame Duration Overall

Pooled analyses make the heterogeneity of trial length explicit. The network meta-analysis of seven GLP-1 receptor agonists and polyagonists compared agents studied over differing treatment durations and reported ranked differences in weight-loss outcomes between them (PMID 39305981), while the semaglutide-specific meta-analysis reported weight-loss effects pooled from randomised trials of once-weekly administration (PMID 38923272). Reviewers in this space commonly note that longer exposure periods were where cardiovascular and other clinical endpoints were captured, as in the 39.8-month mean follow-up of the SELECT trial (PMID 37952131) and the 3.8-year median follow-up in LEADER (PMID 27295427), whereas weight-change endpoints were generally captured within 68 weeks (PMID 33567185).

Limits of This Evidence

Several constraints apply to any reading of trial duration. First, the well-characterised long-duration literature concerns a small number of regulated GLP-1 peptides; most research peptides discussed informally have no comparable long-term randomised data, and research-use-only materials are not studied under these protocols. Second, trial participants were selected by inclusion criteria and monitored throughout, so durations reported in a protocol describe a supervised research setting. Third, the study populations differed — adults with obesity and no diabetes in STEP 1 (PMID 33567185), adults with type 2 diabetes in LEADER (PMID 27295427) — so duration and outcome cannot be detached from population. Finally, the discontinuation literature reported what happened after stopping in aggregate, not for any individual (PMID 40186344).

References

• Once-Weekly Semaglutide in Adults with Overweight or Obesity (The New England Journal of Medicine, 2021)
• Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial (JAMA, 2021)
• Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension (Diabetes, Obesity & Metabolism, 2022)
• Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (The New England Journal of Medicine, 2023)
• Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis (The New England Journal of Medicine, 2024)
• Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity (JAMA Internal Medicine, 2024)
• Discontinuing glucagon-like peptide-1 receptor agonists and body habitus: A systematic review and meta-analysis (Obesity Reviews, 2025)
• Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis (Journal of the ASEAN Federation of Endocrine Societies, 2022)
• Efficacy and safety of once-weekly subcutaneous semaglutide on weight loss in patients with overweight or obesity without diabetes mellitus — a systematic review and meta-analysis of randomized controlled trials (Obesity Reviews, 2024)
• Seven glucagon-like peptide-1 receptor agonists and polyagonists for weight loss in patients with obesity or overweight: an updated systematic review and network meta-analysis of randomized controlled trials (Metabolism, 2024)
• Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (The New England Journal of Medicine, 2016)
• Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes: A Systematic Review of Randomized Controlled Trials (Annals of Internal Medicine, 2025)